Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia

Bibliographic Details
Main Author: Pimazoni-Netto, Augusto [UNIFESP]
Publication Date: 2014
Other Authors: Zanella, Maria Teresa [UNIFESP]
Format: Article
Language: eng
Source: Repositório Institucional da UNIFESP
Download full: http://repositorio.unifesp.br/handle/11600/38356
http://dx.doi.org/10.1089/dia.2014.0092
Summary: Clinical inertia and poor knowledge by many physicians play an important role in delaying diabetes control. Among other guidelines, the Position Statement of the American Diabetes Association/European Association for the Study of Diabetes on Management of Hyperglycemia in Type 2 Diabetes is a respected guideline with high impact on this subject in terms of influencing physicians in the definition of strategic approach to overcome poor glycemic control. But, on the other hand, it carries a recommendation that might contribute to clinical inertia because it can delay the needed implementation of more vigorous, intensive, and effective strategies to overcome poor glycemic control within a reasonable time frame during the evolution of the disease. the same is true with other respected algorithms from different diabetes associations. Together with pharmacological interventions, diabetes education and more intensive blood glucose monitoring in the initial phases after the diagnosis are key strategies for the effective control of diabetes. the main reason why a faster glycemic control should be implemented in an effective and safe way is to boost the confidence and the compliance of the patient to the recommendations of the diabetes care team. Better and faster results in glycemic control can only be safely achieved with educational strategies, structured self-monitoring of blood glucose, and adequate pharmacological therapy in the majority of cases.
id UFSP_985f18cd87982e4db9e1c7ae9e5f3be4
oai_identifier_str oai:repositorio.unifesp.br:11600/38356
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Pimazoni-Netto, Augusto [UNIFESP]Zanella, Maria Teresa [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2016-01-24T14:38:02Z2016-01-24T14:38:02Z2014-11-01Diabetes Technology & Therapeutics. New Rochelle: Mary Ann Liebert, Inc, v. 16, n. 11, p. 768-770, 2014.1520-9156http://repositorio.unifesp.br/handle/11600/38356http://dx.doi.org/10.1089/dia.2014.009210.1089/dia.2014.0092WOS:000343419900011Clinical inertia and poor knowledge by many physicians play an important role in delaying diabetes control. Among other guidelines, the Position Statement of the American Diabetes Association/European Association for the Study of Diabetes on Management of Hyperglycemia in Type 2 Diabetes is a respected guideline with high impact on this subject in terms of influencing physicians in the definition of strategic approach to overcome poor glycemic control. But, on the other hand, it carries a recommendation that might contribute to clinical inertia because it can delay the needed implementation of more vigorous, intensive, and effective strategies to overcome poor glycemic control within a reasonable time frame during the evolution of the disease. the same is true with other respected algorithms from different diabetes associations. Together with pharmacological interventions, diabetes education and more intensive blood glucose monitoring in the initial phases after the diagnosis are key strategies for the effective control of diabetes. the main reason why a faster glycemic control should be implemented in an effective and safe way is to boost the confidence and the compliance of the patient to the recommendations of the diabetes care team. Better and faster results in glycemic control can only be safely achieved with educational strategies, structured self-monitoring of blood glucose, and adequate pharmacological therapy in the majority of cases.Universidade Federal de São Paulo, Kidney & Hypertens Hosp, Diabet Educ & Control Grp, São Paulo, BrazilUniversidade Federal de São Paulo, Kidney & Hypertens Hosp, Dept Endocrinol, São Paulo, BrazilUniversidade Federal de São Paulo, Kidney & Hypertens Hosp, Diabet Educ & Control Grp, São Paulo, BrazilUniversidade Federal de São Paulo, Kidney & Hypertens Hosp, Dept Endocrinol, São Paulo, BrazilWeb of Science768-770engMary Ann Liebert, IncDiabetes Technology & TherapeuticsDiabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertiainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/383562016-01-24 12:38:02.713metadata only accessoai:repositorio.unifesp.br:11600/38356Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652016-01-24T14:38:02Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
title Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
spellingShingle Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
Pimazoni-Netto, Augusto [UNIFESP]
title_short Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
title_full Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
title_fullStr Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
title_full_unstemmed Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
title_sort Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
author Pimazoni-Netto, Augusto [UNIFESP]
author_facet Pimazoni-Netto, Augusto [UNIFESP]
Zanella, Maria Teresa [UNIFESP]
author_role author
author2 Zanella, Maria Teresa [UNIFESP]
author2_role author
dc.contributor.institution.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Pimazoni-Netto, Augusto [UNIFESP]
Zanella, Maria Teresa [UNIFESP]
description Clinical inertia and poor knowledge by many physicians play an important role in delaying diabetes control. Among other guidelines, the Position Statement of the American Diabetes Association/European Association for the Study of Diabetes on Management of Hyperglycemia in Type 2 Diabetes is a respected guideline with high impact on this subject in terms of influencing physicians in the definition of strategic approach to overcome poor glycemic control. But, on the other hand, it carries a recommendation that might contribute to clinical inertia because it can delay the needed implementation of more vigorous, intensive, and effective strategies to overcome poor glycemic control within a reasonable time frame during the evolution of the disease. the same is true with other respected algorithms from different diabetes associations. Together with pharmacological interventions, diabetes education and more intensive blood glucose monitoring in the initial phases after the diagnosis are key strategies for the effective control of diabetes. the main reason why a faster glycemic control should be implemented in an effective and safe way is to boost the confidence and the compliance of the patient to the recommendations of the diabetes care team. Better and faster results in glycemic control can only be safely achieved with educational strategies, structured self-monitoring of blood glucose, and adequate pharmacological therapy in the majority of cases.
publishDate 2014
dc.date.issued.fl_str_mv 2014-11-01
dc.date.accessioned.fl_str_mv 2016-01-24T14:38:02Z
dc.date.available.fl_str_mv 2016-01-24T14:38:02Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Diabetes Technology & Therapeutics. New Rochelle: Mary Ann Liebert, Inc, v. 16, n. 11, p. 768-770, 2014.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/38356
http://dx.doi.org/10.1089/dia.2014.0092
dc.identifier.issn.none.fl_str_mv 1520-9156
dc.identifier.doi.none.fl_str_mv 10.1089/dia.2014.0092
dc.identifier.wos.none.fl_str_mv WOS:000343419900011
identifier_str_mv Diabetes Technology & Therapeutics. New Rochelle: Mary Ann Liebert, Inc, v. 16, n. 11, p. 768-770, 2014.
1520-9156
10.1089/dia.2014.0092
WOS:000343419900011
url http://repositorio.unifesp.br/handle/11600/38356
http://dx.doi.org/10.1089/dia.2014.0092
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Diabetes Technology & Therapeutics
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 768-770
dc.publisher.none.fl_str_mv Mary Ann Liebert, Inc
publisher.none.fl_str_mv Mary Ann Liebert, Inc
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1802764124413755392